Features of zoledronic acid use in the treatment of osteoporosis in elderly patients
https://doi.org/10.37586/2686-8636-3-2025-343-350
Abstract
Osteoporosis is one of the most significant medical problems, especially in the context of global population aging. With increased life expectancy, the number of elderly patients with this pathology is growing, which has significant medical and socio-economic consequences. Osteoporosis is characterized by a decrease in bone mineral density, which significantly increases the risk of fractures, especially in older age groups. These pathological changes not only worsen the quality of life of patients, but also lead to increased healthcare costs and increase the social burden.
About the Author
E. N. Dudinskaya
Pirogov National Research Medical University, Russian Gerontology Research and Clinical Center
Russian Federation
Russian Federation
Dudinskaya Ekaterina Nailievna
Moscow
References
1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 ; 94 (6) : 646–650. doi: 10.1016/0002-9343(93)90218-e.
2. Qaseem A., et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023 ; 176 (2) : 224–238. doi: 10.7326/M22-1034.
3. Belaya Zh. E., Belova K. Yu., Biryukova E. V., et al. Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis. Osteoporosis and Bone Diseases. 2021 ; 24 (2) : 4–47. (In Russ.)]. doi: 10.14341/osteo12930.
4. Camacho P. M., et al. American Association of Clinical Endocrinologists / American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis–2020 update. Endocrine Practice. 2020 ; 26 (Suppl 1) : 1–46.
5. Office of the Surgeon General (US). Bone Health and Osteoporosis: A Report of the Surgeon General. [Electronic resourse]. Rockville (MD): Office of the Surgeon General (US); 2004. Available from: https://www.ncbi.nlm.nih.gov/books/NBK45513/.
6. Raisz L. G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005 ; 115 (12) : 3318– 3325. doi: 10.1172/JCI27071.
7. Rosen C. J. The Epidemiology and Pathogenesis of Osteoporosis. In: Feingold KR, Ahmed SF, Anawalt B, et al., eds. Endotext. South Dartmouth (MA) : MDText.com, Inc. ; 020.
8. Rogers M. J., Mönkkönen J., Munoz M. A. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone. 2020 ; 139 : 115493. doi: 10.1016/j.bone.2020.115493.
9. Reid I. R., Horne A. M., Mihov B., et al. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 ; 379 (25) : 2407–2416. doi: 10.1056/NEJMoa1808082.
10. Black D. M., Delmas P. D., Eastell R., et al. Onceyearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 ; 356 (18) : 1809–1822. doi: 10.1056/NEJMoa067312.
11. Serrano A. J., Begoña L., Anitua E., et al. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis. Gynecol Endocrinol. 2013 ; 29 (12) : 1005–1014. doi: 10.3109/09513590.2013.813468.
12. Davis S., Martyn-St. James M., Sanderson J., et al. A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. Health Technol Assess. 2016 ; 20 (78) : 1–406. doi: 10.3310/hta20780.
13. Zhou J., Ma X., Wang T., Zhai S. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016 ; 27 (11) : 3289–3300. doi: 10.1007/s00198-016-3654-z.
14. Lyles K. W., Colón-Emeric C. S., Magaziner J. S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007 ; 357 (18) : 1799–1809. doi: 10.1056/NEJMoa074941.
15. Yureneva S. V., Averkova V. G. Bisphosphonates for the prevention of osteoporotic fractures in postmenopausal women with osteopenia: a systematic review and meta-analysis. Osteoporosis and Bone Diseases. 2024 ; 27 (1) : 21–34. (In Russ.)]. doi: 10.14341/osteo13150.
16. Watts N. B., Adler R. A., Bilezikian J. P., et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 ; 97 (6) : 1802–1822. doi: 10.1210/jc.2011-3045.
17. Zhou J., Wang T., Zhao X., et al. Comparative Efficacy of Bisphosphonates to Prevent Fracture in Men with Osteoporosis: A Systematic Review with Network Meta-Analyses. Rheumatol Ther. 2016 ; 3 (1) : 117–128. doi: 10.1007/s40744-016-0030-6.
18. Reid D. M., Devogelaer J. P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 ; 373 (9671) : 1253–1263. doi: 10.1016/S0140-6736(09)60250-6.
19. Black D. M., Reid I. R., Boonen S., et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012 ; 27 (2) : 243–254. doi: 10.1002/jbmr.1494.
20. McClung M., Harris S. T., Miller P. D., et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013 ; 126 (1) : 13–20. doi: 10.1016/j.amjmed.2012.06.023.
21. Ganesan K., Goyal A., Roane D. Bisphosphonate. [Updated 2023 Jul 3]. StatPearls. Treasure Island (FL): StatPearls Publishing. 2020.
22. Sharma A., Einstein A. J., Vallakati A., et al. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates. Am J Cardiol. 2014 ; 113 (11) : 1815–1821. doi: 10.1016/j.amjcard.2014.03.008.
23. Lesnyak O. M., Baranova I. A., Belaya Zh. E. Osteoporosis: A guide for physicians (Ed. by O. M. Lesnyak). (2nd ed., rev. and exp.). GEOTAR-Media. 2023. (In Russ.] ISBN: 978-5-9704-7145-6.
24. Greuter S., Schmid F., Ruhstaller T., Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol. 2008 ; 19 (12) : 2091–2092. doi: 10.1093/annonc/mdn653.
25. Anastasilakis A. D., Pepe J., Napoli N., et al. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. J Clin Endocrinol Metab. 2022 ; 107 (5) : 1441–1460. doi: 10.1210/clinem/dgab888.
26. Nicolatou-Galitis O., Kouri M., Papadopoulou E., et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer. 2019 ; 27 (2) : 383–394. doi: 10.1007/s00520-018-4501-x.
27. Ruggiero S. L., Dodson T. B., Aghaloo T., et al. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws2022 Update. J Oral Maxillofac Surg. 2022 ; 80 (5) : 920–943. doi: 10.1016/j.joms.2022.02.008.
28. Campisi G., Mauceri R., Bedogni A., Fusco V. Re: AAOMS Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update. J Oral Maxillofac Surg. 2022 ; 80 (11) : 1723–1724. doi: 10.1016/j.joms.2022.07.149.
29. Khan A. A., Morrison A., Kendler D. L., et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017 ; 20 (1) : 8–24. doi: 10.1016/j.jocd.2016.09.005.
30. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007 ; 22 (10) : 1479–1491. doi: 10.1359/jbmr.0707onj.
31. Shane E., Burr D., Abrahamsen B., et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014 ; 29 (1) : 1–23. doi: 10.1002/jbmr.1998.
32. Black D. M., Geiger E. J., Eastell R., et al. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020 ; 383 (8) : 743–753. doi: 10.1056/NEJMoa1916525.
33. Schilcher J,. Koeppen V., Aspenberg P., Michaëlsson K. Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med. 2014 ; 371 (10) : 974–976. doi: 10.1056/NEJMc1403799.
34. Roca-Ayats N., Balcells S., Garcia-Giralt N., et al. GGPS1 Mutation and Atypical Femoral Fractures with Bisphosphonates. N Engl J Med. 2017 ; 376 (18) : 1794–1795. doi: 10.1056/NEJMc1612804.
35. Pérez-Núñez I., Pérez-Castrillón J. L., Zarrabeitia M. T., et al. Exon array analysis reveals genetic heterogeneity in atypical femoral fractures. A pilot study. Mol Cell Biochem. 2015 ; 409 (1–2) : 45–50. doi: 10.1007/s11010-015-2510-3.
Review
For citations:
Dudinskaya E.N. Features of zoledronic acid use in the treatment of osteoporosis in elderly patients. Russian Journal of Geriatric Medicine. 2025;(3):343-350. (In Russ.) https://doi.org/10.37586/2686-8636-3-2025-343-350
Views:
23
Email this article 